SCHEMBL4672992

SCHEMBL4672992

O=C(C=C(O)c1nn[nH]n1)c1cn(S(=O)(=O)c2ccc(Cl)cc2)cc1CCc1ccccc1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CES1 P23141 1/20 0.37
NCEH1 Q6PIU2 1/20 0.37
TBXA2R P21731 1/20 0.36
ALDH1A1 P00352 3/20 0.35
GAA P10253 1/20 0.35
MEN1 O00255 2/20 0.35
KMT2A Q03164 2/20 0.35
PSEN1 P49768 1/20 0.35
PSEN2 P49810 1/20 0.35
APH1B Q8WW43 1/20 0.35
NCSTN Q92542 1/20 0.35
APH1A Q96BI3 1/20 0.35
PSENEN Q9NZ42 1/20 0.35
LMNA P02545 2/20 0.33
POLB P06746 1/20 0.32
CXCR3 P49682 2/20 0.32
NPSR1 Q6W5P4 1/20 0.32
GRM4 Q14833 1/20 0.32
MMP2 P08253 1/20 0.32
EPHX2 P34913 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4679976 0.91 CES1 (0.37) CES1NCEH1ALDH1A1GAAMEN1
SCHEMBL4675163 0.86 SGMS1 (0.35) ALDH1A1GAAMEN1KMT2APSEN1
SCHEMBL4674121 0.81 TBXA2R (0.39) CES1NCEH1TBXA2RALDH1A1GAA
SCHEMBL4676460 0.80 CES1 (0.43) CES1NCEH1
SCHEMBL4671894 0.79 LMNA (0.33) LMNACXCR3GRM4
SCHEMBL4676571 0.77 SGMS1 (0.35) ALDH1A1GAAMEN1KMT2ALMNA
SCHEMBL4677991 0.77 ALDH1A1 (0.51) ALDH1A1PSEN1PSEN2APH1BNCSTN
SCHEMBL4674218 0.76 CES1 (0.40) CES1NCEH1ALDH1A1
SCHEMBL4679350 0.76 CES1 (0.39) CES1NCEH1
SCHEMBL4674667 0.76 CES1 (0.39) CES1NCEH1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1142872-B1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO (JP) 2008-10-15 EP disclosed
US-7098201-B2 Heteroaromatic derivatives having an inhibitory activity against HIV integrase SHIONOGI & CO., LTD. (JP) 2006-08-29 US disclosed
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase FUJISHITA TOSHIO (JP) 2004-01-01 US disclosed
US-6645956-B1 1-(5-(4-fluorobenzyl)furan-2-yl)-3-hydroxy-3-(1H-1,2,4-triazol-3 -yl)-propenone; viricides; AIDS treatment SHIONOGI & CO., LTD. (JP) 2003-11-11 US disclosed
US-6620841-B1 Furan or benzofuran derivatives substituted with triazole; acquired immunodeficiency syndrome (AIDS) SHIONOGI & CO., LTD. (JP) 2003-09-16 US disclosed
CN-1335834-A Aromatic heterocyclic compounds having HIV integrase inhibitory activity SHIONOGI & CO (JP) 2002-02-13 CN disclosed
EP-1142872-A1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO., LTD. (JP) 2001-10-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase RCOR1, BCOR, CYP8B1 CES1 445/4885NCEH1 1046/4885TBXA2R 2734/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.